Release Date: November 21, 2016
Expiration Date: November 21, 2017

Expected time to complete this activity as designed: 1.5 hours

There are no fees for participating in or receiving credit for this online activity.

Program Overview

The treatment of multiple myeloma (MM) has changed dramatically in the past several years, with numerous innovations resulting in significant improvement in outcomes and long-term survival for many patients. Despite the new advances, however, significant challenges remain, particularly in patients with relapsed/refractory multiple myeloma (RRMM). To support an increased understanding of new therapeutic choices in the treatment of RRMM and to provide practical education that delivers up-to-date information, expert faculty will share their latest insights and experiences. During this activity, recorded from a live meeting in Chicago in September 2016, we will discuss recent advances in the treatment of relapsed/refractory disease and how to navigate among the current agents to find the right treatment option for your patients. This program will describe new agents used in practice today, review current guidelines, share best practices, and review patient-centered treatment strategies in RRMM.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their clinical skills in relapsed/refractory multiple myeloma.

Educational Methods

Lecture – Case study – Audience response system* - Question/answer session – Pre-/Post test

Evaluation

A course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

• Compare and contrast the efficacy and safety of new agents, as well as the regimens that incorporate them, for relapsed/refractory multiple myeloma, including next-generation and new classes of agents, such as HDAC inhibitors and immunotherapeutics, with those that have long been available to practice (knowledge)
  
  
• Recognize patients with relapsed/refractory multiple myeloma that may benefit most from new agents either alone or in specific combination with other therapies (knowledge, competence)
  
  
• Develop individualized treatment and supportive care plans that address individual relapsed/refractory multiple myeloma patient needs, utilizing the new armamentarium of agents and regimens (knowledge, competence, performance, patient outcomes)

Agenda

Module 1
New Treatment Paradigms in Relapsed/Refractory Multiple Myeloma (RRMM) – Philip L. McCarthy, MD

Module 2
Individualizing Therapy with New Agents in RRMM and Individualizing Treatment Goals for Patients with RRMM – Andrzej Jakubowiak, MD, PhD

Module 3
Integrating New Treatment Paradigms into Practice: Real-world Case Vignettes – Andrzej Jakubowiak, MD, PhD

Module 4
Supplemental Panel Discussion (not required for credit) – Andrzej Jakubowiak, MD, PhD, and Philip L. McCarthy, MD

Instructions for Participation and Credit

This activity is eligible for credit through November 21, 2017. After this date, this activity will expire and no further credit will be awarded.

1. Read the target audience, learning objectives, and faculty disclosures.
   
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
   
3. Complete the educational content as designed.
   
4. Certificates awarding AMA PRA Category 1 Credit™, CNE or CPE credit, or certificates documenting attendance, will be issued to participants when an individual completes, submits the post-test and receives a passing score of 70%. Non-physicians will receive a certificate of participation in accordance with state nursing boards, specialty societies, or other professional associations.
   
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
   
6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Andrzej Jakubowiak, MD, PhD
Professor of Medicine
Director, Multiple Myeloma Program
University of Chicago Medical Center
Chicago, Illinois

Dr. Andrzej Jakubowiak earned his medical and doctoral degrees from the Medical Academy in Poznan, Poland. After moving to the United States, he completed a residency in internal medicine at the University of Texas Health Science Center at Houston, followed by two fellowships: one in medicine at Weill Cornell Medical College and one in hematology/oncology at Memorial Sloan Kettering Cancer Center in New York. After joining the faculty in the Section of Hematology/Oncology at the University of Chicago, Dr. Jakubowiak was named Director of the medical center’s Multiple Myeloma Program. He quickly established the University of Chicago as one of the leading programs in the United States in the effort to cure multiple myeloma.

An internationally known expert and the lead investigator for a number of national and international clinical trials, Dr. Jakubowiak’s research has contributed to the development of most of the recently approved drugs and treatment strategies for multiple myeloma. He was awarded the Myeloma Center of the Year Award twice, and received the 2014 Accelerator Award, presented to the best Multiple Myeloma Research Consortium program in North America by the Multiple Myeloma Research Foundation. Dr. Jakubowiak holds leadership positions in multiple professional organizations and is frequently invited to lecture at major national and international meetings, he was recently recognized by his peers as a “Top Cancer Doctor” by Newsweek and by Chicago magazine.

Philip L. McCarthy, MD
Professor of Oncology
Director, Blood and Marrow Transplant Program
Roswell Park Cancer Institute
Buffalo, New York

Dr. Philip McCarthy received his medical degree from Tufts University School of Medicine, Boston, Massachusetts. He completed an internship and residency at Yale-New Haven Hospital, and hematology and medical oncology fellowship training at Brigham and Women's Hospital and Dana Farber Cancer Institute. Dr. McCarthy is Professor of Oncology and Director of the Blood and Marrow Transplant Program at Roswell Park Cancer Institute, Buffalo. He is also Professor of Internal Medicine at the State University of New York at Buffalo.

Dr. McCarthy is a diplomate, American Board of Internal Medicine, with subspecialty certification in medical oncology and hematology, and holds membership in the American Society of Hematology (ASH), American Society for Blood and Marrow Transplantation (ASBMT), American Society of Clinical Oncology (ASCO), American Association of Blood Banking (AABB), and American Association for Cancer Research (AACR). He is associate chair of the Myeloma Committee of the Alliance for Clinical Trials in Oncology (ACTION) and a member of the Transplant Committee. He is an associate editor of the Biology of Blood and Marrow Transplantation journal, as well as an ad hoc reviewer for several journals including Blood, Bone Marrow Transplantation, Journal of Clinical Oncology, Haematologica, Leukemia and Lymphoma, and JNCCN. Dr. McCarthy has published more than 200 peer-reviewed manuscripts and reviews. His major research interests include blood and marrow transplantation, graft-versus-host disease/graft-versus-tumor effect, cancer immunotherapy, and multiple myeloma.

Accreditation

	CME CREDIT The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Texas MD Anderson Cancer Center designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
	CPE CREDIT MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-16-125-H01-P. Knowledge-based CPE activity. In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the login/registration on the home page of this site.
	NURSING CREDIT Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.5 contact hours. Program Number: 16-125-041

CME Disclosure

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. The University of Texas MD Anderson Cancer Center has, through a formal review process, resolved all conflicts of interest prior to this activity. For information on this process, please contact the Department of CME/Conference Management at (713)-792-5357.

All statements and opinions contained herein are solely those of the individual speakers and may not reflect those of The University of Texas MD Anderson Cancer Center.

The University of Texas MD Anderson Cancer Center does not endorse the commercial products, equipment, or services of the program supporters.

CPE, CNE Disclosure

As an organization accredited by the Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. Specific disclosure will be made to the participants prior to the educational activity.

Faculty Disclosures

Faculty, Program Planning Committee Members and CME Activity Reviewers/Approvers have financial interests, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or who may financially support this CME activity, as indicated below.  An asterisk (*) indicates that the faculty’s presentation will include discussion of investigational or off-label uses of a product.

Andrzej J. Jakubowiak, MD, PhD, holds board membership, or has received consulting fees and/or honorarium from Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals, Inc., Karyopharm Therapeutics, sanofi-aventis U.S. LLC., SkylineDx, and Takeda Oncology.

*Philip L. McCarthy, MD, has received grant or research support from Celgene Corporation; honoraria from Bristol-Myers Squibb Company, Celgene, sanofi-aventis U.S. LLC., Takeda Oncology, and The Binding Site Ltd; and holds membership on advisory committees or review panels, and/or board membership from Bristol-Myers Squibb Company, Celgene, Karyopharm Therapeutics, sanofi-aventis, Takeda Oncology, and The Binding Site.

Planning Committee Disclosures

The individuals listed below from the program planning committee reported the following:

Jatin J. Shah, MD, has received grant or research support from Amgen Inc., Array BioPharma, Bristol-Myers Squibb Company, Celgene Corporation, Novartis AG, and Takeda Oncology; was a paid consultant for Amgen, Celgene, Novartis, and Takeda Oncology; and holds membership on advisory committees or review panels, and/or board membership from Amgen and Celgene.

Jonathan L. Kaufman, MD (content development), received grant or research support from Celgene Corporation, Merck & Co., Inc., Novartis AG, and Onyx; was a paid consultant for Celgene; and holds membership on advisory committees or review panels, and/or board membership from Incyte Corporation and Pharmacyclics, Inc.

Sagar Lonial, MD, FACP (content development), has received honoraria from Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals, Inc., Novartis AG, Onyx, and Takeda Oncology.

The individual listed below from The University of Texas MD Anderson Cancer Center reported no relevant financial relationships: Shirley A. Roy, MPH

The individuals listed below from MediCom Worldwide, Inc. reported no relevant financial relationships: Patrick Brooks, PharmD, Joan Meyer, RN, MHA, and Bill Stoff.

CME Activity Reviewer Disclosure

The activity reviewers listed below reported no relevant financial relationships: Larry Driver, MD, Lewis Foxhall, MD, Cynthia Herzog, MD, and Oliver Bogler, PhD (approver).

Physician Payments, Sunshine Act

MediCom Worldwide, Inc. and The University of Texas MD Anderson Cancer Center comply with the Physician Payments Sunshine Act as part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfer of value provided to any covered recipient under the ACA.

The University of Texas MD Anderson Cancer Center Learner Bill of Rights

The University of Texas MD Anderson Cancer Center recognizes that you are a life-long learner who has chosen to engage in continuing medical education to identify or fill a gap in knowledge, skill, or performance. As part of The University of Texas MD Anderson Cancer Center’s duty to you as a learner, you have the right to expect that your continuing educational experience with The University of Texas MD Anderson Cancer Center includes:

• Content that:
  • promotes improvements or quality in healthcare;
  • is valid, reliable, and accurate;
  • offers balanced presentations that are free of commercial bias for or against a product/service;
  • is vetted through a process that resolves any conflicts of interests of planners, teachers, or authors;
  • is driven and based on learning needs, not commercial interests;
  • addresses the stated objectives or purpose; and
  • is evaluated for its effectiveness in meeting the identified educational need.

• A learning environment that:
  • supports learners’ ability to meet their individual needs;
  • respects and attends to any special needs of the learners;
  • respects the diversity of groups of learners; and
  • is free of promotional, commercial, and/or sales activities.

• Disclosure of:
  • relevant financial relationships planners, teachers, and authors have with commercial interests related to the content of the activity; and
  • commercial support (funding or in-kind resources) of the activity.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer^® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows^® Vista, Windows^® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe^® Flash^® Player, Adobe^® Acrobat^®, Windows Media^® Player, and/or Microsoft^® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]

Provided by The University of Texas MD Anderson Cancer Center and MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Inc., Bristol-Myers Squibb Company and Takeda Oncology.

©2016 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.